New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
09:28 EDTRPRXRepros granted end of Phase 2 meeting in late May for Proellex-V by FDA
Repros Therapeutics announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application. Once the meeting is held, the company will report the outcome to the financial community in a timely fashion.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement
March 16, 2015
14:54 EDTRPRXFDA accepting Androxal NDA can be catalyst for Repros, says Brean Capital
Subscribe for More Information
09:28 EDTRPRXRepros Therapeutics reports Q4 EPS (31c), consensus (34c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use